Table 1 Patient characteristics.

From: More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients

Variable

n

Age, median (range)

67 (42–84)

Sex, n (%)

 

Male

24 (80)

Female

6 (20)

ECOG PS, n (%)

 

0

10 (33)

1

16 (53)

2

2 (7)

3

2 (7)

Histopathological diagnosis, n (%)

 

Well differentiated adenocarcinoma

7 (24)

Moderately differentiated adenocarcinoma

19 (63)

Poorly differentiated adenocarcinoma

3 (10)

Unclassifiable

1 (3)

Primary tumour location, n (%)

 

Right side

6 (20)

Left side

22 (73)

Unclassifiable

2 (7)

KRAS, n (%)

 

Mutant

13 (43)

Wild type

15 (50)

ND

2 (7)

BRAF, n (%)

 

Mutant

0 (0)

Wild type

10 (33)

ND

20 (67)

First-line chemotherapy, n (%)

 

mFOLFOX6

19 (63)

CAPOX

11 (37)

  1. CAPOX capecitabine and oxaliplatin, ECOG PS Eastern Cooperative Oncology Group performance status, mFOLFOX6 fluorouracil, oxaliplatin and leucovorin, ND not determined.